Clinical Data earns milestone; NanoViricides raises cash;

> Santen Pharmaceutical has filed for approval of Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension, triggering a $2 million milestone payment to Clinical Data which is due by January 15, 2011. Clinical Data release

> The FDA has rejected Cumberland Pharma's attempt to expand the label on its liver drug Acetadote. Report

> Sanofi-Aventis has bought the rights to a diabetes drug-delivery technology from Ascendis, an American and Danish pharmaceutical company. Sanofi says in a news release that the technology showed "promising results" with insulin in early tests. Story

> REVA closes $63M Aussie IPO. News

> MagForce looks to tackle solid tumors. Article

> When you slurp on your favorite sweet gelatin treat at a holiday party this season (with, or without floating pineapple chunks), think about how that gel you're eating is a liquid rendered solid by, according to AAAS Science Now, "a more or less rigid but disordered network of microscopic particles dispersed throughout its volume." Report

And Finally... A little genetic tinkering led to an unusual creation at the University of Osaka. Scientists developed a line of mice that can sing like a bird. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.